Clinical Trials Logo

Clinical Trial Summary

This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into protocol A.


Clinical Trial Description

Protocol A This will be a randomized, cross-over design comparing low- and high-dose aspirin as well as a non-aspirin platelet inhibitor ticagrelor. This antiplatelet exposure study will be conducted at the DCRU using two separate cohorts: 1) healthy adult volunteers 2) patients with Type 2 diabetes. Subjects within each cohort will but in general will have platelet function testing and biospecimen collection before, four weeks, and eight weeks after low- or high-dose aspirin exposure. Subsequently there will be a period of aspirin washout and a four-week exposure to ticagrelor, a non-aspirin platelet inhibitor. In all subjects and at various time points peripheral blood RNA, purified platelets, DNA, serum, fecal samples and/or plasma will be collected. Protocol B This will be a single arm study of the platelet inhibitor ticagrelor that is essentially the last two visits of Protocol A. This study will be conducted at the DCRU and will only be open to healthy adult volunteers and patients with Type 2 diabetes. Subjects who elect to participate in this protocol will follow the protocol outlined in Figure 2 and in general will have platelet function testing and biospecimen collection before and four weeks after exposure to ticagrelor, a non-aspirin platelet inhibitor. In all subjects and at various time points (see Figure 2 and Table 2) peripheral blood RNA, purified platelets, DNA, serum, and/ plasma will be collected. In order to align the visits with that of Protocol A, the two visits under this protocol will be labelled V4 and V5. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05278637
Study type Interventional
Source Duke University
Contact
Status Completed
Phase Early Phase 1
Start date November 1, 2013
Completion date December 5, 2016

See also
  Status Clinical Trial Phase
Recruiting NCT00978159 - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Phase 4
Completed NCT04153760 - Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Early Phase 1
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Recruiting NCT06185621 - The Effect of Aspirin on Recurrent Acute Pancreatitis N/A
Completed NCT01582217 - Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition N/A
Recruiting NCT01268917 - The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass Phase 3
Recruiting NCT03450317 - Influence of Aspirin on Human Gut Microbiota Composition and Metabolome N/A
Completed NCT03424408 - Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin N/A
Completed NCT03871517 - INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE Phase 4
Recruiting NCT05802940 - Low Dose Aspirin Alerts in High-Risk Pregnancies N/A
Recruiting NCT05702463 - Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II Phase 1
Completed NCT01900639 - Aspirin AM or PM: Effect on Circadian Rhythm of Platelet Reactivity Phase 4
Recruiting NCT03188471 - Preventive Application of GnRH Antagonist on Early OHSS Phase 4
Recruiting NCT03005704 - Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets N/A
Recruiting NCT03785015 - When Should Low-dose Aspirin be Resumed After Peptic Ulcer Bleeding? N/A
Completed NCT00753753 - VerifyNow French Registry N/A
Recruiting NCT04356326 - Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy Phase 3
Recruiting NCT04214990 - Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients Phase 3
Enrolling by invitation NCT04365309 - Protective Effect of Aspirin on COVID-19 Patients Phase 2/Phase 3
Completed NCT05512546 - The Prevention of Thromboembolic Complications Associated With Coil Embolization